SPHS Oversold, Filling the Gap, cash/share > share price

Sophiris Bio had a Phase III drug trial test showing the drug was not effective and the market overreacted. The chart has a cash/share value (mrq) of $1.74, the float is 16.78 Million Shares (note today's volume alone is a large part of that), so with a tiny float, more cash per share on hand than the market price, and upcoming results for new Phase III results for other products, one can see why people are buying this up right now.